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Objectives: To audit the proportion of clinical trials
that had been publically registered and, of the
completed trials, the proportion published.
Setting: 2 major research institutions supported by
the National Institute of Health Research (NIHR).
Primary and secondary outcome measures: The
proportion of trials reporting results within 12 months,
24 months and ‘ever’. Factors associated with non-
publication were analysed using logistic regression.
Inclusion criteria: Phases 2–4 clinical trials
identified from internal documents and publication
lists.
Results: In total, 286 trials were identified. We could
not find registration for 4 (1.4%) of these, all of which
were completed and published. Of the trials with a
registered completion date pre-January 2015, just over
half (56%) were published, and half of these were
published within 12 months (36/147, 25%). For some
trials, information on the public registers was found to
be out-of-date and/or inaccurate. No clinical trial
characteristics were found to be significantly associated
with non-publication. We have produced resources to
facilitate similar audits elsewhere.
Conclusions: It was feasible to conduct an internal
audit of registration and publication in 2 major
research institutions. Performance was similar to, or
better than, comparable cohorts of trials sampled from
registries. The major resource input required was
manually seeking information: if all registry entries
were maintained, then almost the entire process of
audit could be automated—and routinely updated—for
all research centres and funders.
INTRODUCTION
The public registration of clinical trials, and
the timely publication of their results, are
widely accepted as scientiﬁc and moral obli-
gations. Guidelines issued by a range of regu-
latory bodies, including the WHO,1 the
World Medical Association,2 the US Food
and Drug Administration (FDA)3 and the
European Commission4 have encouraged
and latterly mandated these activities for
funders and triallists. Since 2013, the UK’s
Health Research Authority will explicitly not
approve applications to conduct clinical trials
that are not registered.5
The AllTrials Campaign developed in
response to professional, public and patient
concern regarding the lack of progress in
this area, and calls for all trials to be regis-
tered and reported.6 It is estimated that
about a half of all trials go unreported7 and
two cohort studies from 2012 to 2015 have
found that only a ﬁfth of trials registered on
clinicaltrials.gov reported results within
1 year of completion.8 9 This is despite the
Strengths and limitations of this study
▪ To our knowledge, this is the first published
audit of clinical trial registration and publication
performance for two major research institutions.
▪ By using internal records, it was possible to
assess if there were any unregistered, unpub-
lished trials: many other studies of trial registra-
tion have worked from published papers, making
it impossible to assess this.
▪ There was a limited response from investigators
when contacted to supplement the limited infor-
mation contained within the internal records.
▪ We have produced and shared resources to facili-
tate similar audits elsewhere.
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reporting of results within 12 months of completion
being mandatory for all trials that fall under the FDA
Amendments Act legislation.3 Estimates of non-
registration are harder to collect, since unregistered and
unpublished trials are hard to identify, but one cohort
study found that only half of all trials published in major
medical journals were properly registered, and a quarter
were not registered at all.10
In 2015, the WHO published a landmark position
statement, requiring all trials to make their methods and
results available.1 Speciﬁcally the WHO stated that
results from clinical trials should be publicly reported
within 12 months of their end, and that results from
previously unpublished trials should be made publicly
available. They also stated that organisations and govern-
ments should implement measures to achieve this.
We have previously suggested that research organisa-
tions and companies should routinely audit themselves
to ensure all trials’ methods and results are made pub-
licly accessible.11 Inspired by the AllTrials Campaign, the
Patient Involvement Working Group at the National
Institute of Health Research (NIHR) Oxford Biomedical
Research Centre (BRC) and the NIHR Oxford
Musculoskeletal Biomedical Research Unit (BRU) sug-
gested that the BRC/BRU’s own track record of register-
ing clinical trials and publishing their results should be
scrutinised, and funded this work.
METHODS
We aimed to assess the proportion of clinical trials that
had been publically registered and the proportion of
completed trials that had been published. We also
aimed to assess the proportion published within
12 months of trial completion.
We undertook a retrospective audit of all clinical trials
receiving support from the NIHR Oxford BRC and/or
BRU. These organisations are collaborations between
the University of Oxford and the Oxford University
Hospitals National Health Service (NHS) Trust. As
recognised centres of research excellence, they have
been awarded over £160 million pounds of public funds
via the NIHR since their inception in 2007.12 13 The
BRC and BRU fund-speciﬁc projects (in whole or in
part) and also invest in research staff and infrastructure
to improve the translation of basic scientiﬁc develop-
ments into clinical beneﬁt. Therefore, the trials
included in this audit may have been funded wholly or
in part by the BRC/BRU and/or have received input
from BRC/BRU-funded researchers and/or been con-
ducted in BRC/BRU-supported facilities.
We focused the audit on phases 2, 3 and 4 clinical
trials as earlier phase trials are exempt from the require-
ments to be registered and published.3 Individual trials
that covered both phases 1 and 2 were included. We con-
ducted the registration and publication searches in
January 2015 and used the BRC/BRU annual activity
reports submitted to the NIHR between 2009 and 2014
to compile a list of trials. We cross-checked this list using
a publication list (BRC) and publically available annual
reports (BRU). We undertook the audit using four dis-
tinct steps:
Step 1: creating the inventory of clinical trials
One researcher (ACT) reviewed the details of the pro-
jects contained within the annual activity reports to
remove duplicates and then assessed eligibility by deter-
mining study type and clinical trial phase, where applic-
able. Records were supplemented with data in publically
accessible registries/databases if needed (ﬁgure 1).
Eligibility queries were resolved by discussion between
CJH and ACT: if this was not possible, we sent an email
enquiry to the project lead investigator.
Step 2: populating the inventory and assessing
registration
One researcher (ACT) searched the four major clinical
trial registries using the full trial title or, if not available,
combinations of other identifying features (eg, drug
name and target condition; ﬁgure 1). The registries
were searched in a speciﬁc order for pragmatic reasons
based on their size and their inclusion of the informa-
tion required for the audit. We contacted the trial inves-
tigator if we could not locate a registry entry for their
project. We populated the audit inventory with the fol-
lowing variables, extracted directly from the register
where possible: ofﬁcial title, abbreviated title, trial identi-
ﬁcation numbers, sponsor details, funding bodies, trial
status, completion date (anticipated or actual), presence
of any uploaded results and any listed publications.
Step 3: verification of the inventory
One researcher (ACT) checked the completeness of the
inventory using a list of BRC-supported research publica-
tions and publically available BRU annual reports. We
asked BRU investigators to supplement the details of the
trials mentioned due to the limited information avail-
able in the annual reports. A list of phases 2, 3 and 4
trials was produced and cross-referenced against the
inventory.
Step 4: assessing publication
Based on our inventory, one researcher (ACT) searched
for publications for clinical trials that gave a completion
date before January 2015. For trials registered on clini-
caltrials.gov, the overall study completion date was used;
if not entered, the primary outcome completion date
was used instead. In addition to publications listed on
the registry and results posted in tabular format to clini-
caltrials.gov, we also searched PubMed (http://www.
ncbi.nlm.nih.gov/pubmed) for articles arising from the
completed trials. Those describing the protocol design
or analysis plan were excluded. Finally, if it was not pos-
sible to locate a publication for a clinical trial with a
completion date of before January 2014, we contacted
the BRC/BRU investigators directly. This cut-off was
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chosen because the European Union (EU; since 2014)
and the FDA (since 2007) require clinical trials to post
results within 12 months following the end date of the
trial.3 4
Data analysis
Analysis was conducted with Stata MP V.14. The data
were described, and logistic regression used to examine
trial characteristics associated with slow/non-publication.
A logistic regression model was built using ‘sponsor
type’, ‘phase’ and ‘sample size’ as explanatory variables.
This model was constructed prior to analysing the data,
rather than by using forward selection, and used widely
available variables from registry entries, so that future
audits can use the same methods and code to produce
comparable results.
RESULTS
Based on step 1 of our method, we assessed 1255 pro-
jects for eligibility and compiled an initial inventory of
247 clinical trials: table 1 shows that 215 were BRC
supported, 29 were BRU supported and 3 trials received
support from both organisations.
The veriﬁcation method, outlined in step 3, identiﬁed
a further 39 (16%) trials. Therefore, the total number
of trials supported by the BRC and/or BRU and
included in the audit was 286 with over 217 000 partici-
pants worldwide. Of these, 90 (31%) were sponsored by
Oxford (University and/or Oxford University Hospitals
NHS Trust) and 108 (38%) were sponsored by industry.
The remainder were sponsored by other academic, char-
itable or non-industry sources. (The sponsor is respon-
sible for the initiation, management and/or ﬁnancing
of a clinical trial.)
Registration
We could not ﬁnd public registry entries for six trials
identiﬁed (4 in step 1 and 2 trials in step 3), and so we
contacted these investigators. One was in fact a duplicate
of an already identiﬁed trial and another was registered
on the EU Clinical Trials Register (EuCTR) database,
although no results had been produced when we
searched the register.
Figure 1 Hierarchy of sources used to verify records. EuCTR, EU Clinical Trials Register; ICTRP, International Clinical Trials
Registry Platform; ISRCTN, International Standard Randomised Controlled Trial Number.
Table 1 The number and registration status of Biomedical Research Centre (BRC)/Biomedical Research Unit
(BRU)-supported clinical trials included in the audit
BRC (n=215) BRU (n=29) Both (n=3) Total (n=247)
Inventory—step 1 n Per cent n Per cent N Per cent n Per cent
Unregistered 2 0.9 0 0 0 0 2 0.8
Verification—step 3
BRC (n=34) BRU (n=5) Both (n=0) Total (n=39)
n Per cent n Per cent N Per cent n Per cent
Unregistered 2 5.9 0 0 – – 2 5.1
Combined
BRC (n=249) BRU (n=34) Both (n=3) Total (n=286)
n Per cent n Per cent N Per cent n Per cent
Unregistered 4 1.6 0 0 0 0 4 1.4
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Therefore, in total, we identiﬁed 4/286 (1.4%)
unregistered trials, all of which had been completed and
published: One was an e-health intervention described
as a pilot study; another was a surgical trial conducted in
2009 at which time the lead investigator (incorrectly)
believed it did not require registration. The ﬁnal two
were oncology trials which, although started in the early
2000s, were published in 2011 and 2014, after launch of
the International Committee of Medical Journal Editor’s
policy requiring clinical trial registration.14
Publication
One hundred and forty-seven (147) trials had a
pre-January 2015 completion date (118 identiﬁed via
step 1 and 29 identiﬁed via step 3).
We found academic publications reporting results for
65 (44%); 3 (2.0%) had summary results uploaded on
the clinical trials register; 12 trials (8.2%) had both.
We contacted investigators for the 37 (33%) of the
112 trials with a completion date of pre-January 2014,
12 months prior to the audit date, for which no publica-
tion had been identiﬁed and where publication was
therefore overdue (ﬁgure 2). No reply was received
from 14 triallists, and these projects were therefore clas-
siﬁed as unpublished. Of the 23 trials for which
responses were received: 17 (74%) trials were unpub-
lished due to delays; 6 were in press; 6 had manuscripts
under journal review; 3 trials were undergoing analysis;
2 reported they were still collecting data; 2 trials had
been discontinued; and for 2 trials the reason for
non-publication was not known by the Oxford-based
collaborator or not given. The remaining two investiga-
tors supplied publication details that our search had
missed and these were added to the audit database.
Overall, of the trials with a pre-January 2015 comple-
tion date, 82 of the 147 (56%) were published or had
uploaded summary results, with the BRC and BRU
achieving 54% and 67% publication, respectively
(table 2).
Publication or uploading of trial results within
12 months of the registered completion date was less
common, as reported in ﬁgure 3: 36 of the 147 trials
(25%) were published within 12 months and 48 (33%)
within 24 months. The longest duration to publication
was 54 months. Figure 4 shows that over the 7 years
follow-up reported here, there has been no clear trend
in the number of trials reporting results within
12 months of completion.
Accuracy and completeness of registry data
Fourteen of the 282 registered trials were registered on
EuCTR which does not require an expected completion
date to be uploaded at the time of registration. A
further 77 trials were registered on the ISRCTN register
(known originally as the International Standard
Randomised Controlled Trial Number but now broader
in scope). This allows only one completion date to be
registered, which is not ideal for trials with short-term
and long-term follow-up.
Using the overall study completion date for our calcu-
lations, 12 trials appeared to have been published earlier
than the completion date on their registry entry, giving a
negative ﬁgure for publication delay. One publication
described interim trial results while another ﬁve
reported results for primary outcomes. Investigations
into the reasons for early publication of the remaining
trials found that registry data were either incorrect or
out of date: one trial was discontinued, and the data col-
lected were published early, but the trial was marked as
‘completed’ rather than ‘terminated’ and the comple-
tion date left unchanged; one trial was listed as a
Figure 2 Audit flow chart of clinical trials that were overdue
publication.
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two-arm design, but on closer inspection the data were
apparently two similar trials, at two different sites, with
apparently incorrect use of trial identiﬁcation numbers
in the relevant documents; one trial registry entry erro-
neously contained a link to the results for a different
trial of a similar design; two trials were registered as
having follow-up time of 5–6 and 5 years, respectively,
then published outcome data with median follow-up 4.3
and 3.8 years, respectively, but the registered completion
dates remained unchanged; and one trial was entered
onto two registries, with a completion date on ISRCTN
2 years earlier than that on clinicaltrials.gov.
Given these discrepancies, a random sample of 10
trials was selected from the list of trials with associated
publications. Their outcomes, completion dates,
sponsor and trial sites were compared between registry
entry and publication, to assess whether any further
trial publications on registry entries had been attached
to the wrong trial on the registry: none in the sample
had been.
Factors associated with publication/non-publication of
results
Table 3 presents the results of the logistic regression: no
variables (sponsor type, trial phase or sample size) were




It was feasible to conduct an internal audit of registra-
tion and publication of clinical trials in two major
research institutions, covering almost 300 trials. Working
from internal documents, we did not ﬁnd any evidence
of active clinical trials that were unregistered; however,
we did identify four completed trials that had been
Figure 3 The time from registered completion date to
publication of Biomedical Research Centre (BRC)/Biomedical
Research Unit (BRU)-supported phases 2–4 trials.
Figure 4 The publication status of Biomedical Research
Centre (BRC)/Biomedical Research Unit (BRU)-supported
phases 2–4 trials by registered completion year.
Table 2 Publication status of Biomedical Research Centre (BRC)/Biomedical Research Unit (BRU)-supported trials with a
registered pre-January 2015 completion date
BRC (n=101) BRU (n=17) Total (n=118)
Inventory—step 1 n Per cent n Per cent n Per cent
Published (within 12 months of trial completion) 17 16.8 4 23.5 21 17.8
Published (over 12 months of trial completion) 29 28.7 7 41.2 36 30.5
Unpublished 55 54.4 6 35.3 61 51.7
Verification—step 3
BRC (n=28) BRU (n=1) Total (n=29)
n Per cent n Per cent n Per cent
Published (within 12 months of trial completion) 14 50.0 1 100 15 51.7
Published (over 12 months of trial completion) 10 35.7 0 0 10 34.5
Unpublished 4 14.3 0 0 4 13.8
Combined
BRC (n=129) BRU (n=18) Total (n=147)
n Per cent n Per cent n Per cent
Published 70 54.2 12 66.7 82 55.7
Unpublished 59 45.7 6 33.3 65 44.2
Tompson AC, et al. BMJ Open 2016;6:e009285. doi:10.1136/bmjopen-2015-009285 5
Open Access
group.bmj.com on January 30, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
published but not registered. The majority of completed
trials were eventually published, but not all within 12 or
even 24 months of completion. Lastly, some registry data
were found to be incorrect or out of date.
Strengths
To our knowledge, this is the ﬁrst published audit of
publication performance for major research institutions.
By using internal records as a data source, it was possible
to get good data on trial registration as well as publica-
tion: many other studies of completeness of registration
have worked backwards from published papers, there-
fore making it impossible to identify and assess registra-
tion status of any unpublished trials.
Our audit builds on the foundations laid in Oxford
25 years ago by Easterbrook et al15 who tracked studies
following their approval by the local research ethics
committee and found evidence of publication bias.
Since then, the requirements for clinical trial transpar-
ency and the supporting infrastucture have developed
greatly, both prompting the need for—and enabling—
audits such as ours.
Limitations
The response rate from investigators when contacted
with queries was poor, and consequently the eligibility of
six projects listed in the BRC and BRU internal records
remains unresolved. We hope that future response rates
will improve as institutional audits of the registration
and publication of clinical trials become the norm with
trial registration and publication become indisputable
steps in research for patient beneﬁt. In addition, the
audit did not examine the contents of trial publications,
speciﬁcally whether the published outcomes match
those prespeciﬁed in the registry entry, a known source
of research bias.10 Similarly, the quality of the informa-
tion entered by investigators into clinical trial registries
was not scrutinised for all trials. Classifying non-
pharmaceutical trials was difﬁcult. As has been noted
elsewhere, clearer guidance is needed on how to
Table 3 Characteristics of published and unpublished trials
OR
n Published, % Crude (95% CI) p Value Adjusted (95% CI) p Value
Sponsor type Non-industry 103 52, 49.51 1 1
Industry 44 27, 61.36 1.56 (0.76 to 3.20) 0.227 2.03 (0.88 to 4.69) 0.099
Phase 1, 2 12 5, 41.67 0.74 (0.21 to 2.67) 0.650 0.89 (0.24 to 3.33) 0.860
2 49 24, 48.98 1 1 –
2, 3 6 5, 83.33 5.21 (0.57 to 47.90) 0.145 5.13 (0.52 to 50.33) 0.160
3 26 12, 46.15 0.89 (0.34 to 2.32) 0.816 0.68 (0.23 to 2.05) 0.492
4 14 9, 64.29 1.87 (0.55 to 6.40) 0.316 2.10 (0.59 to 7.50) 0.256
Not applicable 40 24, 60.00 1.56 (0.67 to 3.64) 0.301 1.95 (0.77 to 4.99) 0.161
Sample size
(quartiles)
First (4–52) 34 17, 50.00 0.95 (0.38 to 2.38) 0.910 1.07 (0.41 to 2.77) 0.894
Second (52–116) 39 20, 51.28 1 – 1 –
Third (116–387) 36 19, 52.78 1.06 (0.43 to 2.63) 0.900 0.98 (0.36 to 2.64) 0.969
Fourth (387–15 460) 37 23, 62.16 1.56 (0.63 to 3.89 0.340 1.48 (0.51 to 4.31) 0.474
Figure 5 Organisational recommendations following the audit findings. HRA, Health Research Authority; NHS, National
Health Service.
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categorise trials (including pilot studies) and the
requirements for their registration.16
How do publication performance of trials supported by the
NIHR Oxford BRC and BRU compare with other
institutions?
A 2014 systematic review evaluated the publication rates
of 22 cohorts of trials that had been identiﬁed via trial
registries.17 These cohort studies were published
between 2008 and 2013, and together included a range
of medical specialties and over 16 000 trials. The propor-
tion of trials published as peer-reviewed journal articles
ranged from 13% to 90% with the review authors calcu-
lating that the weighted pooled proportion would be
54% after a minimum follow-up time of 24 months after
trial completion (95% CI 42% to 66%, I2 98.9%). There
were 86 BRC/BRU trials with a pre-January 2013 com-
pletion date, thus allowing 24 months of follow-up time;
of these, 67 (78%) had been published, exceeding the
average performance in other published cohorts.
For timely publication, two cohort studies have been
published looking at trials registered on clinicaltrials.gov
to establish compliance with the FDA Amendment Act
2007, which requires publication for certain trials within
12 months of completion.8 9 These two previous studies
estimate publication rates at 12 months to be 22% and
13%, respectively, compared with 25% for our cohort.
However, both previous studies exempted trials that were
not covered by the FDA Amendment Act (such as trials
on drugs that have not yet been licensed), and so may
overestimate performance for timely publication across
all trials when compared with the methods of our com-
prehensive audit.
Given the provenance of this study (the patient co-led
and focused Patient Involvement Working Group of the
NIHR Oxford BRC and BRU), it is important to note:
while timely publication of trials on registries and in pro-
fessional publications is paramount, we are also working to
identify how best to create lay-friendly information for
those seeking information about trials and their outcomes,
and how best to ensure it is made available to them.18
Implications for practice
Based on the audit ﬁndings, the audit team and BRC/
BRU Directors produced a set of recommendations to
improve the transparency regarding which clinical trials
receive BRC/BRU support and to encourage their timely
publication (ﬁgure 5). The BRC/BRU Directors have
committed to improving performance in these areas, and
we are conﬁdent that with some simple changes and
renewed prioritisation, this can be achieved.
More widely, routine ongoing audit has been proposed
as a method by which institutions, sponsors and research
funders can monitor their performance on registering
and publishing trials, and use this to improve stan-
dards.19 20 We have demonstrated that this is feasible
and encourage other organisations to do the same. Our
full methods (including template audit materials and
analytic code) are available as an online supplementary
appendix. Figure 6 describes what we have learnt having
conducted the audit.
We are also aware of several local audits that have
been conducted by various organisations since the
current wave of renewed interest in trials transparency
began. These include audits by sections of the Health
Research Authority; the NIHR; and the Medical
Research Council (to produce an estimate of publication
bias for a 2012 UK parliamentary inquiry into trials
transparency).21 To date, these audits all remain unpub-
lished: we would welcome others sharing their methods,
ﬁndings and insights. The major resource required for
conducting our audit was the manual collection of data,
cross-checking different sources and seeking clariﬁcation
from individual researchers. If registry entries were con-
sistently completed, and the information reliably main-
tained, it would be possible to automate almost the
entire process of the audit. It would also then be trivial
to derive—and display—an updated monthly perform-
ance metric, generated automatically by analytic code
running on registry data. If all registry data at all institu-
tions were maintained, this would in turn provide a
‘transparency dashboard’ on timely publication—a uni-
versally recognised metric of transparency—for easy
comparison of different institutions, funders, drugs,
principal investigators and ﬁelds of medicine.
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